Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial

Reuters10-14

Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial

Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575914512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575914512","market":"us","top_or_hot":-1,"title":"Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL10bQWb:1","article_id":"2575914512","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575914512","pubTimestamp":1760439668,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","MCRB":"Seres Therapeutics, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技"},"translate_title":"Seres Therapeutics宣布SER-155在减少同种异体干细胞移植患者血流感染方面的积极1b期数据，计划进行2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MCRB":0.9},"content_text":"Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial\n    \n\n        Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575914512","isCrawlerRequest":true}